New therapeutic approaches for metastatic thyroid carcinoma

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Williams Textbook of Endocrinology

Melmed, S., & Polonsky, K. С. (2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,716 · see citing works

Increasing Incidence of Thyroid Cancer in the United States, 1973-2002

Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,379 · see citing works

International Histological Classification of Tumours

Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,047 · see citing works

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,014 · see citing works

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

Pacini, F., Schlumberger, M. J., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W. M., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,970 · see citing works

Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

Durante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670 · see citing works

Tyrosine Kinases as Targets for Cancer Therapy

Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works

Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long‐term Outcome in 2444 Consecutively Treated Patients

HAY, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Maurer, M. S., McIver, B., Mullan, B. P., Oberg, A. L., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6612-1 · Cited by 731 · see citing works

RAS Point Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma

Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 711 · see citing works

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

Fagin, J. A., MATSUO, K., Karmakar, A., Chen, D. L., Tang, S., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 647 · see citing works

Histological Typing of Thyroid Tumours

Hedinger, C. E. (1988) · Springer eBooks · doi:10.1007/978-3-642-61383-8 · Cited by 634 · see citing works

Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis

Leboulleux, S., Rubino, C., Baudin, É., Caillou, B., Hartl, D. M., Bidart, J., Travagli, J., & Schlumberger, M. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0285 · Cited by 585 · see citing works

Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning

Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gönen, M., Strausś, H. W., Tuttle, R. M., Drucker, W. D., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 582 · see citing works

Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer

Machens, A., Hinze, R., Thomusch, O., & Dralle, H. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0176-3 · Cited by 507 · see citing works

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 475 · see citing works

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation

Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414 · see citing works

Radioiodsne-131 In the Diagnosis and Treatment of Metastatic Weil Differentiated Thyroid Cancer

Maxon, H. R., & Smith, H. S. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30317-7 · Cited by 409 · see citing works

Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features

Bunone, G., Vigneri, P. G., Mariani, L., Butó, S., Collini, P., Pilotti, S., Pierotti, M. A., & Bongarzone, I. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65515-0 · Cited by 395 · see citing works

Morphologic characteristics of benign and malignant adrenocortical tumors

van Slooten, H., Schaberg, A., Smeenk, D., & Moolenaar, A. J. (1985) · Cancer · doi:10.1002/1097-0142(19850215)55:4 · Cited by 322 · see citing works

Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid Carcinomas

Bernier, M., Leenhardt, L., Hoang, C., Aurengo, A., Mary, J., Ménégaux, F., Enkaoua, E., Turpin, G., Jacques Chiras, C., Saillant, G., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7390 · Cited by 295 · see citing works

Survival and Death Causes in Differentiated Thyroid Carcinoma

Eustatia‐Rutten, C. F. A., Corssmit, E. P. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., & Smit, J. W. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1322 · Cited by 287 · see citing works

AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts

Polverino, A. J., Coxon, A., Starnes, C. O., Diaz, Z., DeMelfi, T. M., Wang, L., BREADY, J. V., Estrada, J., Cattley, R. C., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 286 · see citing works

An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases

Kim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279 · see citing works

Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades

Dinneen, S. F., Välimäki, M. J., Bergstralh, E. J., Goellner, J. R., Gorman, C. A., & HAY, I. D. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608252 · Cited by 273 · see citing works

Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases

Kitamura, Y., Shimizu, K., Nagahama, M., Sugino, K., Ozaki, O., Mimura, T., Ito, K., Ito, K., & Tanaka, S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6115 · Cited by 271 · see citing works

Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism

Filetti, S., Bidart, J., Arturi, F., Caillou, B., Russo, D., & Schlumberger, M. J. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410443 · Cited by 268 · see citing works

Textbook of Endocrine Surgery

Clark, O. H., Duh, Q., Kebebew, E., Gosnell, J. E., & Shen, W. T. (2016) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/12798 · Cited by 266 · see citing works

Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.

Mandell, R. B., Mandell, L. Z., & Link, C. J. (1999) · PubMed · Cited by 253 · see citing works

Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.

Boland, A., Ricard, M., Opolon, P., Bidart, J., Yeh, P., Filetti, S., Schlumberger, M. J., & Perricaudet, M. (2000) · PubMed · Cited by 232 · see citing works

Thyroid-hormone therapy and thyroid cancer: a reassessment

Biondi, B., Filetti, S., & Schlumberger, M. J. (2005) · Nature Clinical Practice Endocrinology &#38 Metabolism · doi:10.1038/ncpendmet0020 · Cited by 221 · see citing works

Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.

Casara, D., Rubello, D., Saladini, G., Masarotto, G., Favero, A., Girelli, M. E., & Busnardo, B. (1993) · PubMed · Cited by 212 · see citing works

Restoration of Iodide Uptake in Dedifferentiated Thyroid Carcinoma: Relationship to Human Na+/I− Symporter Gene Methylation Status1

Venkataraman, G. M., Yatin, M., Marcinek, R., & Ain, K. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5815 · Cited by 204 · see citing works

Public attitudes toward cancer pain

Levin, D. N., Cleeland, C. S., & Dar, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9 · Cited by 199 · see citing works

Gene Methylation in Thyroid Tumorigenesis

Xing, M. (2006) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 176 · see citing works

Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997)

Colonna, M., Grosclaude, P., Remontet, L., Schvartz, C., Macé-Lesec'h, J., Velten, M., Guizard, A., Trétarre, B., Buémi, A., Arveux, P., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00110-7 · Cited by 175 · see citing works

Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine

Pacini, F., Cetani, F., Miccoli, P., Mancusi, F., Ceccarelli, C., Lippi, F., Martino, E., & Pinchera, A. (1994) · World Journal of Surgery · doi:10.1007/bf00353775 · Cited by 172 · see citing works

Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0690 · Cited by 168 · see citing works

Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na+/I- Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells

Kitazono, M., Robey, R. W., Zhan, Z., Sarlis, N. J., Skarulis, M. C., Aikou, T., Bates, S. E., & Fojo, T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7621 · Cited by 163 · see citing works

Iodide Uptake and Experimental 131I Therapy in Transplanted Undifferentiated Thyroid Cancer Cells Expressing the Na+/I- Symporter Gene

Shimura, H., Haraguchi, K., Miyazaki, A., Endo, T., & Onaya, T. (1997) · Endocrinology · doi:10.1210/endo.138.10.5571 · Cited by 159 · see citing works

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy

Fagin, J. A. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05895 · Cited by 154 · see citing works

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

Lennard, C. M., Patel, A. D., Wilson, J., Reinhardt, B. J., Tuman, C., Fenton, C., Blair, E., Francis, G. L., & Tuttle, R. M. (2001) · Surgery · doi:10.1067/msy.2001.112592 · Cited by 148 · see citing works

Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma

Travagli, J. P., Cailleux, A.-F., Ricard, M., Baudin, É., Caillou, B., Parmentier, C., & Schlumberger, M. J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5014 · Cited by 144 · see citing works

Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo

Ouyang, B., Knauf, J. A., Smith, E. P., Zhang, L., Ramsey, T., Yusuff, N., Batt, D. B., & Fagin, J. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1729 · Cited by 139 · see citing works

ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma

Vidal, M., Wells, S. A., Ryan, A. J., & Cagan, R. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4561 · Cited by 139 · see citing works

Interferon-α-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects

Carella, C., Mazziotti, G., Amato, G., Braverman, L., & Roti, E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0627 · Cited by 132 · see citing works

Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.

Williams, S. D., Birch, R., & Einhorn, L. H. (1986) · PubMed · Cited by 126 · see citing works

Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?

Grüning, T., Tiepolt, C., Zöphel, K., Bredow, J., Kropp, J., & Franke, W. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480395 · Cited by 125 · see citing works

Restoration of Iodide Uptake in Dedifferentiated Thyroid Carcinoma: Relationship to Human Na+/I- Symporter Gene Methylation Status

Venkataraman, G. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.7.2449 · Cited by 119 · see citing works

Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas

Rouxel, A., Hejblum, G., Bernier, M., Boëlle, P., Ménégaux, F., Mansour, G., Hoang, C., Aurengo, A., & Leenhardt, L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032004 · Cited by 116 · see citing works

Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with Retinoids

Haugen, B. R., Larson, L. L., Pugazhenthi, U., Hays, W. R., Klopper, J. P., Kramer, C. A., & Sharma, V. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030770 · Cited by 113 · see citing works

Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy

Droz, J., Schlumberger, M. J., Rougier, P. R., Ghosn, M., Gardet, P., & Parmentier, C. (1990) · Tumori Journal · doi:10.1177/030089169007600513 · Cited by 110 · see citing works

Silencing of the Tumor Suppressor GeneSLC5A8Is Associated withBRAFMutations in Classical Papillary Thyroid Carcinomas

Porra, V., Ferraro‐Peyret, C., Durand, C., Selmi‐Ruby, S., Giroud, H., Berger-Dutrieux, N., Decaussin‐Petrucci, M., Peix, J., Bournaud, C., Orgiazzi, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1394 · Cited by 104 · see citing works

Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo

Luong, Q. T., O’Kelly, J., Braunstein, G. D., Hershman, J. M., & Koeffler, H. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0367 · Cited by 98 · see citing works

Preventable reoperations for persistent and recurrent papillary thyroid carcinoma

Kouvaraki, M. A., Lee, J. E., Shapiro, S. E., Sherman, S. I., & Evans, D. B. (2004) · Surgery · doi:10.1016/j.surg.2004.06.045 · Cited by 98 · see citing works

AKT in Thyroid Tumorigenesis and Progression

Shinohara, M., Chung, Y. J., Saji, M., & Ringel, M. D. (2006) · Endocrinology · doi:10.1210/en.2006-0937 · Cited by 97 · see citing works

Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer

Braga‐Basaria, M., & Ringel, M. D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021863 · Cited by 94 · see citing works

Textbook of Endocrine Surgery

(2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0139-7.x5001-7 · Cited by 94 · see citing works

Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer

Santini, F., Bottici, V., Elisei, R., Montanelli, L., Mazzeo, S., Basolo, F., Pinchera, A., & Pacini, F. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011151 · Cited by 91 · see citing works

Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour

de la Torre, N. G., BULEY, I. D., Wass, J. A. H., & Turner, H. E. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01210 · Cited by 89 · see citing works

Effects of Histone Acetylation on Sodium Iodide Symporter Promoter and Expression of Thyroid-Specific Transcription Factors

Puppin, C., D’Aurizio, F., D'Elia, A. V., Cesaratto, L., Tell, G., Russo, D., Filetti, S., Ferretti, E., Tosi, E., Mattei, T., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0128 · Cited by 88 · see citing works

Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

Santoro, M., & Carlomagno, F. (2006) · Nature Clinical Practice Endocrinology &#38 Metabolism · doi:10.1038/ncpendmet0073 · Cited by 81 · see citing works

Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study

Schoenberger, J., Grimm, D. G., Kossmehl, P. P., Infanger, M., Kurth, E., & Eilles, C. (2003) · Endocrinology · doi:10.1210/en.2003-1228 · Cited by 81 · see citing works

Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis

Mitsiades, C. S., Kotoula, V., Poulaki, V., Sozopoulos, E., Negri, J. M., Charalambous, E., Fanourakis, G., Voutsinas, G. E., Tseleni‐Balafouta, S., & Mitsiades, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0055 · Cited by 62 · see citing works

Radiation Combined With Antiangiogenic and Antivascular Agents

OʼReilly, M. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.006 · Cited by 62 · see citing works

Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma

Mrózek, E., Kloos, R. T., Ringel, M. D., Kresty, L. A., Snider, P., Arbogast, D., Kies, M. S., Munden, R. F., Busaidy, N. L., Klein, M. J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2498 · Cited by 54 · see citing works

Gene Therapy for Thyroid Cancer: Current Status and Future Prospects

Spitzweg, C., & Morris, J. C. (2004) · Thyroid · doi:10.1089/105072504323150732 · Cited by 52 · see citing works

Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs

Teunissen, J. J. M., Kwekkeboom, D. J., & Krenning, E. P. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.11.005 · Cited by 43 · see citing works

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

Schott, M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01133 · Cited by 37 · see citing works

Inhibition of Metabolic Activity in Papillary Thyroid Carcinoma by a Somatostatin Analogue

Robbins, R. J., Hill, R. H., Wang, W., Macapinlac, H. A., & Larson, S. M. (2000) · Thyroid · doi:10.1089/thy.2000.10.177 · Cited by 35 · see citing works

Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer

Younes, M. N., Yazici, Y. D., Kim, S., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0793 · Cited by 35 · see citing works

Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43–9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study

Kloos, R. T., Ringel, M. D., Knopp, M. V., Heverhagen, J. T., Rittenberry, J., Weldy, L., Arbogast, D., Collamore, M., King, M., Young, D. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5534 · Cited by 30 · see citing works

Surgical Management of Advanced Thyroid Cancer Invading the Aerodigestive Tract

Dralle, H. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0139-7.50038-7 · Cited by 20 · see citing works

Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study

Boughton, D., Rosen, L. S., Vugt, A. V., Kurzrock, R., Eschenberg, M. J., Wiezorek, J. S., Ingram, M., Wang, D., Stepan, D. E., & Herbst, R. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3030 · Cited by 18 · see citing works

Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways

Bounacer, A., McGregor, A., Skinner, J. W., BOND, J. A., Poghosyan, Z., & Wynford‐Thomas, D. (2004) · Oncogene · doi:10.1038/sj.onc.1208085 · Cited by 17 · see citing works

A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer

Kim, S., Rosen, L. S., Cohen, E. E. W., Cohen, R. B., Forastiere, A. A., Silva, A. M., Liau, K., ARCHER, R. L., Bycott, P. W., & Vokes, E. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5529 · Cited by 17 · see citing works

Guidelines for radioiodine therapy of differentiated thyroid cancer

Luster, M., Clarke, S. E., Dietlein, M., Laßmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 725 · see citing works

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Carr, L. L., Mankoff, D. A., Goulart, B., Eaton, K. D., Capell, P. T., Kell, E., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422 · see citing works

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 418 · see citing works

Thyroid carcinoma: molecular pathways and therapeutic targets

Nikiforov, Y. E. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.10 · Cited by 394 · see citing works

Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis

Nikiforova, M. N., & Nikiforov, Y. E. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.83 · Cited by 277 · see citing works

B-Raf V600E and thrombospondin-1 promote thyroid cancer progression

Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 166 · see citing works

A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma

Chou, A. S. Y., Fraser, S., Toon, C. W., Clarkson, A., Sioson, L., Farzin, M., Cussigh, C., Aniss, A. M., O’Neill, C. J., Watson, N., et al. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000368 · Cited by 109 · see citing works

ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer

Schlumberger, M. J., & Sherman, S. I. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0631 · Cited by 109 · see citing works

New targets and therapeutic approaches for endocrine malignancies☆

Fassnacht, M., Kreissl, M. C., Weismann, D., & Allolio, B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.013 · Cited by 104 · see citing works

Targeted Radionuclide Therapy

Ersahin, D., Doddamane, I., & Cheng, D. (2011) · Cancers · doi:10.3390/cancers3043838 · Cited by 104 · see citing works

BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression

Nucera, C., Lawler, J., & Parangi, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3844 · Cited by 96 · see citing works

Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas

Pérot, G., Soubeyran, I., Ribeiro, A., Bonhomme, B., Savagner, F., Boutet-Bouzamondo, N., Hostein, I., Bonichon, F., Godbert, Y., & Chibon, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087170 · Cited by 94 · see citing works

An update on molecular biology of thyroid cancers

Ömür, Ö., & Baran, Y. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.007 · Cited by 93 · see citing works

SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2

Shaik, S., Nucera, C., Inuzuka, H., Gao, D., Garnaas, M., Frechette, G. M., Harris, L. N., Wan, L., Fukushima, H., Husain, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112446 · Cited by 93 · see citing works

Antitumor effects of anlotinib in thyroid cancer

Ruan, X., Shi, X., Dong, Q., Yu, Y., Hou, X., Song, X., Wei, X., Chen, L., & Gao, M. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0558 · Cited by 91 · see citing works

Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients

Versari, A., Sollini, M., Frasoldati, A., Fraternali, A., Filice, A., Froio, A., Asti, M., Fioroni, F., Cremonini, N., Putzer, D., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0225 · Cited by 91 · see citing works

Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

O’Neill, C. J., Oucharek, J. J., Learoyd, D., & Sidhu, S. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0190 · Cited by 74 · see citing works

Contemporary management of papillary carcinoma of the thyroid gland

Rosenbaum, M. A., & McHenry, C. R. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.3.317 · Cited by 73 · see citing works

MicroRNAs in the thyroid

Boufraqech, M., Kłubo-Gwieździńska, J., & Kebebew, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.10.001 · Cited by 71 · see citing works

Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer

Isham, C. R., Bossou, A. R., Negron, V. C., Fisher, K. E., Kumar, R., Marlow, L. A., Lingle, W. L., Smallridge, R. C., Sherman, E. J., Suman, V. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004358 · Cited by 69 · see citing works

Molecular Targeted Therapies of Aggressive Thyroid Cancer

Ferrari, S. M., Fallahi, P., Politti, U., Materazzi, G., Baldini, E., Ulisse, S., Miccoli, P., & Antonelli, A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00176 · Cited by 68 · see citing works

Spinal metastasis in thyroid cancer

Ramadan, S., Ugas, M. A., Berwick, R., Notay, M., Cho, H., Jerjes, W., & Giannoudis, P. V. (2012) · Head & Neck Oncology · doi:10.1186/1758-3284-4-39 · Cited by 66 · see citing works

Thyroid computed tomography imaging: pictorial review of variable pathologies

Saeedan, M. B., Aljohani, I. M., Khushaim, A., Bukhari, S. Q., & Elnaas, S. T. (2016) · Insights into Imaging · doi:10.1007/s13244-016-0506-5 · Cited by 65 · see citing works

S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI Imaging

Nipp, M., Elsner, M., Balluff, B., Meding, S., Sarioglu, H., Ueffing, M., Rauser, S., Unger, K., Höfler, H., Walch, A. K., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0815-6 · Cited by 63 · see citing works

New therapies for dedifferentiated papillary thyroid cancer

Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58 · see citing works

Targeting RET for thyroid cancer therapy

Lanzi, C., Cassinelli, G., Nicolini, V., & Zunino, F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.10.033 · Cited by 60 · see citing works

Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review)

Cao, Z., Gao, Q., Fu, M., Ni, N., Pei, Y., & Ou, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.9856 · Cited by 57 · see citing works

Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia

Schlumberger, M.-J., Filetti, S., & HAY, I. D. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00014-6 · Cited by 56 · see citing works

[90Yttrium‐DOTA]‐TOC response is associated with survival benefit in iodine‐refractory thyroid cancer

Iten, F., Müller-Stich, B. P., Schindler, C., Rasch, H. F., Rochlitz, C. F., Oertli, D., Maëcke, H. R., Müller‐Brand, J., & Walter, M. A. (2009) · Cancer · doi:10.1002/cncr.24272 · Cited by 56 · see citing works

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Broecker‐Preuss, M., Müller, S. P., Britten, M. W., Worm, K., Schmid, K. W., Mann, K., & Führer, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1186-0 · Cited by 56 · see citing works

Imaging for staging and management of thyroid cancer

King, A. D. (2008) · Cancer Imaging · doi:10.1102/1470-7330.2008.0007 · Cited by 54 · see citing works

PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art

Piccardo, A., Trimboli, P., Foppiani, L., Treglia, G., Ferrarazzo, G., Massollo, M., Bottoni, G., & Giovanella, L. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09491-2 · Cited by 52 · see citing works

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways

Gunda, V., Bucur, O., Varnau, J., Borre, P. V., Bernasconi, M. J., Khosravi‐Far, R., & Parangi, S. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.78 · Cited by 51 · see citing works

IMAGING IN ENDOCRINOLOGY: 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up

Salvatori, M., Biondi, B., & Rufini, V. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0066 · Cited by 51 · see citing works

Role of B-RafV600E in differentiated thyroid cancer and preclinical validation of compounds against B-RafV600E

Nucera, C., Goldfarb, M. R., Hodin, R. A., & Parangi, S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.01.003 · Cited by 50 · see citing works

Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines

Piscazzi, A., Costantino, E., Maddalena, F., Natalicchio, M. I., Gerardi, A. M. T., Antonetti, R., Cignarelli, M., & Landriscina, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3269 · Cited by 49 · see citing works

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?

Nucera, C., Lawler, J., Hodin, R. A., & Parangi, S. (2010) · Oncotarget · doi:10.18632/oncotarget.210 · Cited by 48 · see citing works

Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy

Lapa, C., Werner, R. A., Schmid, J.-S., Papp, L., Zsótér, N., Biko, J., Reiners, C., Herrmann, K., Buck, A. K., & Bundschuh, R. A. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.12.006 · Cited by 46 · see citing works

MicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer

Lee, J. C., Gundara, J. S., Glover, A. R., Serpell, J. W., & Sidhu, S. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0135 · Cited by 45 · see citing works

Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors

Eszlinger, M., Krohn, K., Hauptmann, S., Dralle, H., Giordano, T. J., & Paschke, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0201 · Cited by 42 · see citing works

Multi-targeted approach in the treatment of thyroid cancer

Chen, H. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3062 · Cited by 40 · see citing works

The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions

Riwaldt, S., Bauer, J. W., Pietsch, J., Braun, M., Segerer, J., Schwarzwälder, A., Corydon, T. J., Infanger, M., & Grimm, D. G. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226108 · Cited by 40 · see citing works

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma

Spano, J., Vano, Y.-A., Vignot, S., Rouge, T. D. L. M., Hassani, L., Mouawad, R., Ménégaux, F., Khayat, D., & Leenhardt, L. (2011) · Medical Oncology · doi:10.1007/s12032-011-0070-2 · Cited by 39 · see citing works

Thyroid Cancer: Current Molecular Perspectives

Giusti, F., Falchetti, A., Franceschelli, F., Marini, F., Tanini, A., & Brandi, M. L. (2010) · Journal of Oncology · doi:10.1155/2010/351679 · Cited by 39 · see citing works

Molecular genetics of papillary thyroid carcinoma: great expectations...

Trovisco, V., Soares, P., Preto, A., Castro, P., Máximo, V., & Sobrinho-Simões, M. A. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000500002 · Cited by 37 · see citing works

Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation

Jeong, W., Mo, J., Park, M. W., Choi, I. J., An, S.-Y., Jeon, E.-H., & Ahn, S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.5.16303 · Cited by 37 · see citing works

Prognostic Factors in Patients with Well-Differentiated Thyroid Cancer Presenting with Pulmonary Metastasis

Showalter, T. N., Siegel, B. A., Moley, J. F., Baranski, T., & Grigsby, P. W. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0501 · Cited by 37 · see citing works

Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression

Yu, X.-M., Jaskula‐Sztul, R., Georgen, M. R., Aburjania, Z., Somnay, Y. R., LEVERSON, G. E., Sippel, R. S., Lloyd, R. V., Johnson, B. P., & Chen, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1749 · Cited by 37 · see citing works

Selective use of vandetanib in the treatment of thyroid cancer

Antonelli, A., Fallahi, P., Bari, F. D., Ferrari, S. M., Spisni, R., Materazzi, G., Miccoli, P., & Benvenga, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s72495 · Cited by 36 · see citing works

Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma

Enríquez, J. E., Muñoz-Montero, S. A., Imaz-Rosshandler, I., Huerta-Verde, A. J., Mejía, C., & Lemus, E. H. (2015) · BMC Genomics · doi:10.1186/s12864-015-1372-0 · Cited by 35 · see citing works

Cpt1c regulated by AMPK promotes papillary thyroid carcinomas cells survival under metabolic stress conditions

Wang, R., Yajun, C., Su, D., Gong, B., He, X., Zhou, X., Pang, Z., Cheng, L., Chen, Y., & Yao, Z. (2017) · Journal of Cancer · doi:10.7150/jca.21148 · Cited by 34 · see citing works

Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer

Middendorp, M., & Grünwald, F. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.10.006 · Cited by 34 · see citing works

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy

Ke, Y., & Xiang, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s187240 · Cited by 32 · see citing works

Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience

Tsimberidou, A. M., Vaklavas, C., Wen, S., Hong, D. S., Wheler, J. J., Ng, C. S., Naing, A., Tse, S., Busaidy, N. L., Markman, M. M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0743 · Cited by 32 · see citing works

Thyroid Cancer in Young Adults

Ying, A. K., Huh, W. W., Bottomley, S. J., Evans, D. B., & Waguespack, S. G. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.03.009 · Cited by 31 · see citing works

Coding Molecular Determinants of Thyroid Cancer Development and Progression

Valvo, V., & Nucera, C. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.003 · Cited by 31 · see citing works

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

Broecker‐Preuss, M., Becher-Boveleth, N., Müller, S. P., & Mann, K. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0303-8 · Cited by 30 · see citing works

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells

Chen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29 · see citing works

Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells

Grosse, J., Warnke, E., Wehland, M., Pietsch, J., Pöhl, F., Wise, P. M., Magnusson, N. E., Eilles, C., & Grimm, D. G. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0937-0 · Cited by 29 · see citing works

Refractory thyroid carcinoma: which systemic treatment to use?

Faugeras, L., Pirson, A., Donckier, J. E., Michel, L. A., Lemaire, J., Vandervorst, S., & D'Hondt, L. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017752853 · Cited by 27 · see citing works

Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer

Chougnet, C., Brassard, M., Leboulleux, S., Baudin, É., & Schlumberger, M. J. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.04.008 · Cited by 26 · see citing works

Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules

Mekel, M., Nucera, C., Hodin, R. A., & Parangi, S. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.08.029 · Cited by 25 · see citing works

A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis

Zou, X., Gao, F., Wang, Z., Zhang, H., Liu, Q., Jiang, L., Xin Min, Z. H. O. U., & Zhu, W. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001107 · Cited by 23 · see citing works

Referral bias in thyroid cancer surgery: Direction and magnitude

Machens, A., Hauptmann, S., & Dralle, H. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.07.006 · Cited by 23 · see citing works

Targeted therapies for advanced thyroid cancer

Puxeddu, E., Romagnoli, S., & Dottorini, M. E. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328340cf94 · Cited by 22 · see citing works

Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma

Khan, M. N., Sharfuzzaman, A., & Mostafa, M. G. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.131661 · Cited by 21 · see citing works

Bone Metastases of Differentiated Thyroid Cancer: The Importance of Early Diagnosis and 131I Therapy on Prognosis

Zanotti‐Fregonara, P., Rubello, D., & Hindié, E. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054163 · Cited by 20 · see citing works

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments

Mohamed, A. F., González, J. M., & Fairchild, A. O. (2015) · Journal of Thyroid Research · doi:10.1155/2015/438235 · Cited by 20 · see citing works

Investigational Therapies for Metastatic Thyroid Carcinoma

Tuttle, R. M., & Leboeuf, R. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0055 · Cited by 20 · see citing works

Radioiodine Imaging and Treatment in Thyroid Disorders

Griggs, W.-S., & Divgi, C. R. (2008) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2008.03.008 · Cited by 19 · see citing works

Standard and Emerging Therapeutic Approaches for Thyroid Malignancies

Brown, R. L. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.03.011 · Cited by 19 · see citing works

Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells

Broecker‐Preuss, M., Viehof, J., Jastrow, H., Becher-Boveleth, N., Führer, D., & Mann, K. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0186-x · Cited by 18 · see citing works

Impact of Sunitinib on Human Thyroid Cancer Cells

Grosse, J., Warnke, E., Pöhl, F., Magnusson, N. E., Wehland, M., Infanger, M., Eilles, C., & Grimm, D. G. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350132 · Cited by 18 · see citing works

Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma

Wang, C., Diao, H., Ren, P., Wang, X., Wang, Y., & Zhao, W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00640 · Cited by 17 · see citing works

Review: What Can Be Expected from Nuclear Medicine Tomorrow?

Barbet, J., Kraeber‐Bodéré, F., & Chatal, J. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.010-u · Cited by 17 · see citing works

Enhanced photodynamic effect of cobalt(iii) dipyridophenazine complex on thyrotropin receptor expressing HEK293 cells

Saha, S., Majumdar, R., Dighe, R. R., & Chakravarty, A. R. (2010) · Metallomics · doi:10.1039/c0mt00028k · Cited by 17 · see citing works

Age disparities in referrals to specialist surgical care for papillary thyroid cancer

Machens, A., & Dralle, H. (2009) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2009.07.008 · Cited by 17 · see citing works

Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice

Díez, J. J., Iglesias, P., Alonso, T., & Grande, E. (2014) · Endocrine · doi:10.1007/s12020-014-0356-1 · Cited by 15 · see citing works

Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome.

Toubert, M., Hindié, E., Rampin, L., AL-NAHHAS, A. M., & Rubello, D. (2007) · PubMed · Cited by 15 · see citing works

Targeted molecular therapies in thyroid carcinoma

Romagnoli, S., Moretti, S., Voce, P., & Puxeddu, E. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000900002 · Cited by 13 · see citing works

Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma

Elboğa, U., Özkaya, M., Sayıner, Z. A., & Celen, Y. Z. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213627 · Cited by 12 · see citing works

Targeted Radionuclide Therapy

Ersahin, D., Doddamane, I., & Cheng, D. (2011) · Cancers · doi:10.3390/cancers3043858 · Cited by 12 · see citing works

Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature

Kaldrymides, P., Kostoglou‐Athanassiou, I., Gkountouvas, A., Veniou, E., & Ziras, N. (2010) · Endocrine · doi:10.1007/s12020-009-9290-z · Cited by 11 · see citing works

Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients

Atallah, V., Hocquelet, A., Cao, C. D., Zerdoud, S., de la Fouchardière, C., Bardet, S., Italiano, A., Dierick-Gallet, A., Leduc, N., Bonichon, F., et al. (2016) · Thyroid · doi:10.1089/thy.2015.0648 · Cited by 10 · see citing works

A ‘silent’ skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman

Huang, T., Cheng, Y.-K., Chen, T.-W., Hsu, Y.-C., Liu, E., & Chen, H. (2017) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0100 · Cited by 10 · see citing works

Kinase inhibitors for refractory thyroid cancers

Schlumberger, M. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70226-6 · Cited by 10 · see citing works

Inflammatory Myofibroblastic Tumor in the Thyroid Gland: A Retrospective Case Series Study and Literature Review

Shi, P., Zhang, L., Shi, H., & Wu, Y. (2022) · Oncology Research and Treatment · doi:10.1159/000524489 · Cited by 9 · see citing works

Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer

Abuqbeitah, M., Demır, M., Kabasakal, L., Çavdar, İ., Uslu, L., Yeyin, N., Razavikhosroshahi, S., & Sönmezoğlu, K. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000900 · Cited by 9 · see citing works

Targeted therapy in refractory thyroid cancer

Schlumberger, M. J. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70190-3 · Cited by 9 · see citing works

Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3′-oxime (7BIO)

Broecker‐Preuss, M., Becher-Boveleth, N., Gall, S., Rehmann, K., Schenke, S., & Mann, K. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0251-8 · Cited by 9 · see citing works

Emerging Therapies in Sight for the Fight against Dedifferentiated Thyroid Cancer

Benvenga, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2799 · Cited by 9 · see citing works

Prise en charge des cancers réfractaires de la thyroïde

Schlumberger, M. J. (2011) · Annales d Endocrinologie · doi:10.1016/j.ando.2011.03.020 · Cited by 8 · see citing works

Clinicopathological significance of chemokine receptor CXCR4 expression in papillary thyroid carcinoma: a meta-analysis

Wu, Z., Cao, Y. Z., Jiang, X., Li, M., Wang, G., Yang, Y., & Lü, K. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02709-8 · Cited by 8 · see citing works

Management of differentiated thyroid carcinoma with bone metastasis: a case report and review of the Chinese literature

Zhang, W., Liu, D., Feng, C.-C., Zhou, C.-B., Zhan, C., Que, R., & Chen, L. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400124 · Cited by 7 · see citing works

Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer

Rendl, G., Rettenbacher, L., Schweighofer-Zwink, G., Hehenwarter, L., & Pirich, C. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1111-8927 · Cited by 7 · see citing works

Positron Emission Tomography/Computed Tomography in Thyroid Cancer

Bal, C., Chakraborty, D., & Khan, D. (2022) · PET Clinics · doi:10.1016/j.cpet.2021.12.004 · Cited by 7 · see citing works

A protective factor against lymph node metastasis of papillary thyroid cancer: Female gender

Shi, P., Yang, D., Liu, Y., Zhao, Z., Song, J., Shi, H., Wu, Y., & Jing, S. (2022) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.10.001 · Cited by 7 · see citing works

Novel approaches in the treatment of thyroid cancer

Brown, R. L., & Cohen, E. E. W. (2008) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2008.01.002 · Cited by 7 · see citing works

Different CXCR4 Expression According to Various Histologic Subtype of Papillary Thyroid Carcinoma

Shin, D. Y., Kim, K. J., Ku, C. R., Lee, M. K., Jee, S. I., Chung, W. Y., & Lee, E. J. (2013) · Endocrine Pathology · doi:10.1007/s12022-013-9259-6 · Cited by 7 · see citing works

The Association Between Lymph Node Metastasis and Molecular Markers in Differentiated Thyroid Cancer

Aydoğan, B. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.55 · Cited by 7 · see citing works

Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.

Dadu, R., & Cabanillas, M. E. (2012) · PubMed · Cited by 44 · see citing works

Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

O’Neill, C. J., Oucharek, J. J., Learoyd, D., & Sidhu, S. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0190 · Cited by 74 · see citing works

Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer

Ibrahim, E., & Busaidy, N. L. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000349 · Cited by 38 · see citing works

Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer

Chougnet, C., Brassard, M., Leboulleux, S., Baudin, É., & Schlumberger, M. J. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.04.008 · Cited by 26 · see citing works

Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer

Kreissl, M. C., Janssen, M. J. R., & Nagarajah, J. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190819 · Cited by 69 · see citing works